Stratos Wealth Partners’s ADMA Biologics ADMA Stock Holding History

Stratos Wealth Partners’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-40,035	Closed	-$155K	–	1127
2022 Q4	$155K	Buy	40,035 +35	+0.1%	+$108	﹤0.01%	1067
2022 Q3	$97K	Hold	40,000	–	–	﹤0.01%	1076
2022 Q2	$79K	Hold	40,000	–	–	﹤0.01%	1147
2022 Q1	$73K	Buy	+40,000	New	+$62.4K	﹤0.01%	1228
2021 Q4	–	Sell	-20,000	Closed	-$23K	–	1255
2021 Q3	$23K	Hold	20,000	–	–	﹤0.01%	1171
2021 Q2	$32K	Hold	20,000	–	–	﹤0.01%	1175
2021 Q1	$35K	Buy	+20,000	New	+$45.8K	﹤0.01%	1102
2020 Q4	–	Sell	-20,000	Closed	-$48K	–	1077
2020 Q3	$48K	Hold	20,000	–	–	﹤0.01%	1002
2020 Q2	$59K	Hold	20,000	–	–	﹤0.01%	973
2020 Q1	$58K	Buy	+20,000	New	+$69.1K	﹤0.01%	897

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Stratos Wealth Partners's ADMA Position: Q1 2023 in Review

Stratos Wealth Partners sold out of ADMA Biologics (ADMA) in Q1 2023, closing a stake of 40,035 shares — an estimated $155K sold.

Stratos Wealth Partners first reported a position in ADMA in Q1 2020 and held it in 10 quarters. The position peaked at $155K in Q4 2022. 163 funds tracked by Wall St. Rank hold ADMA as of Q1 2023.

Stratos Wealth Partners reported no remaining ADMA Biologics position as of Q1 2023 after selling out during the quarter.
Stratos Wealth Partners sold 40,035 ADMA Biologics shares in Q1 2023, an estimated $155K.
Stratos Wealth Partners first reported a position in ADMA Biologics in Q1 2020 and held it in 10 quarters.
Stratos Wealth Partners's ADMA Biologics position peaked at $155K in Q4 2022.
163 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2023.

Based on Stratos Wealth Partners's 13F filing for Q1 2023, filed 27 Apr 2023.